Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2019

View Archived Issues

Bragsin inhibits BRAG2-mediated Arf GTPase activation in vitro in a membrane-dependent manner

MIT discovers high-affinity peptide-based PPI inhibitors using noncanonical amino acids

Pericytes rebuild muscle mass

Protecting the brain in sepsis

Melatonin receptor structure solved

Potential chemokine biomarkers for proliferative vitreoretinopathy in primary retinal detachment

Novel dimerizing agent immunoreceptor complex NKG2D-DARIC shows robust in vitro activity

New therapeutic protein reduces B-cell signaling

New gene therapy VTX-803 shows preclinical efficacy for the treatment of PFIC3

Patient recruitment ongoing in phase III study of sitravatinib plus nivolumab in NSCLC

Initiation of first-in-human study of YL-13027 in solid tumors

AMAL Therapeutcs to evaluate ATP-128 plus BI-754091 in phase I study

Cidara Therapeutics presents initial data from phase II STRIVE study of rezafungin

Urinary EGF as a new biomarker of progression of renal disease in children with nephrotic syndrome

Galectin-4 as a novel biomarker in infants with intestinal disease

Samumed launches phase III clinical program for lorecivivint in knee osteoarthritis

Novel LFA-1 antagonist VVN-001 for treating dry eye disease

Phase III study of Trelegy Ellipta in uncontrolled asthma meets primary endpoint

FDA issues second complete response letter for Barhemsys

FDA approves Tibsovo for newly diagnosed IDH1 mutant AML ineligible for intensive chemotherapy

Qternmet XR approved in U.S. for type 2 diabetes

Shanghai De Novo Pharmatech patents adenosine A2A receptor antagonists

Merck & Co. presents indoleamine 2,3-dioxygenase 1 inhibitors

Boehringer Ingelheim identifies new Bruton tyrosine kinase inhibitors

New PTP-2C inhibitors synthesized at REVOLUTION Medicines

Bristol-Myers Squibb discloses new STING agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...